real-time news and commentary for investors
Tuesday, Sep 17
EU approves Sanofi's Lemtrada multiple sclerosis drug
- The European Comission has granted market authorization to Sanofi's (SNY) Lemtrada drug for the treatment of multiple sclerosis.
- The approval, the first globally, follows that for Aubagio in August, and Sanofi intends to launch the medicines in the EU soon.
- Sanofi expects the FDA to decide on Lemtrada's approval later this year. (PR)